Merck Serono Completes Patient Enrollment in SETTLE, a Phase III Pivotal Clinical Trial of Safinamide in Advanced Parkinson's Disease

GENEVA, Switzerland, July 29, 2011 /PRNewswire/ --

• Study will evaluate efficacy and safety of safinamide as add-on therapy to a stable dose of levodopa

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its partner Newron Pharmaceuticals S.p.A announced today that patient enrollment has been completed in the SETTLE^[1] study. This randomized, double-blind, placebo-controlled, international phase III pivotal trial is designed to evaluate the efficacy and safety of a dose range of safinamide (50-100mg once daily), as an adjunctive therapy to a stable dose of levodopa. A total of 549 patients with mid- to late-stage Parkinson's disease with motor fluctuations were randomized in the study.

The SETTLE study is part of the clinical development program of safinamide in Parkinson's disease, together with completed studies 015, 016, 017 and 018, as well as the ongoing MOTION study. This clinical program is designed to investigate safinamide as an add-on therapy to dopamine agonist therapy in patients with early Parkinson's disease and as an add-on to levodopa therapy in patients with advanced Parkinson's disease.

Merck Serono has exclusive worldwide rights to develop, manufacture and commercialize safinamide in Parkinson's disease, Alzheimer's disease and other therapeutic applications, as per the agreement signed with Newron in 2006.

^[1]SETTLE: SafinamidE Treatment as add-on To LEvodopa in idiopathic Parkinson's disease with motor fluctuations

SETTLE study design

The study is a six-month (24-week), randomized, double-blind, placebo-controlled international Phase III trial. It enrolled 549 patients with mid- to late-stage idiopathic Parkinson's disease (more than three years of disease duration) treated with a stable dose of levodopa for at least four weeks, who have motor fluctuations with more than one and a half hours of "OFF" time during the day. Additionally, patients may be receiving concomitant treatment with stable doses of a dopamine agonist, a COMT inhibitor, an anticholinergic and/or amantadine. After a four-week levodopa dosage stabilization phase, study participants were randomized in one of the two arms of the trial (1:1) to receive either safinamide or matching placebo tablets, as adjunctive treatment.

The primary endpoint of the trial is the change in daily "ON" time, as assessed by the recordings of diary cards maintained by patients after prior training, from baseline to week 24. Secondary endpoints include changes in measures of activities of daily living, global clinical status and health-related quality of life.

About safinamide

Safinamide is an alpha-aminoamide that is currently being developed by Merck Serono and Newron as an add-on therapy to dopamine agonists or to levodopa in patients with early or mid- to late-stage Parkinson's disease (PD). It is believed to have both dopaminergic and non-dopaminergic activities, including selective and reversible inhibition of monoamine oxidase B (MAO-B), activity-dependent sodium channel antagonism and inhibition of glutamate release in vitro. Studies are ongoing to better understand safinamide's actions in patients with PD.

Safinamide is currently in Phase III for PD and its clinical program includes:

- The ongoing MOTION (safinaMide add-On To dopamine agonists for early Idiopathic ParkinsON's) study: a phase III, double-blind, placebo-controlled randomized six-month trial to evaluate efficacy and safety of two doses of safinamide (50mg/day or 100 mg/day), as add-on to dopamine agonist therapy versus dopamine agonist therapy alone, in early stage PD patients and the MOTION extension 18-month phase III, double-blind, placebo-controlled extension study designed to provide data on the long-term safety and efficacy.

- The ongoing SETTLE (SafinamidE Treatment as add-on To LEvodopa) study: a Phase III, double-blind, placebo-controlled six-month trial to evaluate efficacy and safety of a dose range of safinamide (50-100 mg/day) as add-on to levodopa therapy versus levodopa therapy alone, in mid- to late-stage PD patients.

- The completed 015 study: a phase III, double-blind, placebo-controlled six-month study to evaluate efficacy and safety of a low (50-100mg/day) and high (150-200mg/day) dose range of safinamide as add-on to dopamine agonist therapy versus dopamine agonist therapy alone in early stage PD patients.

- The completed 017 study (the 015 extension study): a phase III, double blind, placebo-controlled, 12-month extension study to evaluate the long-term efficacy and safety of a dose range of safinamide of 50-200mg/day, as add-on to dopamine agonist therapy versus dopamine agonist therapy alone in early stage PD patients

- The 016 study: a phase III, double-blind, placebo-controlled randomized six-month trial to evaluate efficacy and safety of two doses safinamide (50mg/day or 100mg/day) as add-on to levodopa therapy versus levodopa therapy alone, in patients with mid- to late-stage PD experiencing motor fluctuations.

- The completed 018 study (the 016 extension study): a phase III, double-blind, randomized, placebo-controlled, 18-month extension to Study 016, to evaluate the long-term efficacy and safety of a low (50 mg/day) and high (100 mg/day) dose of safinamide, compared with placebo, as add-on treatment to levodopa therapy in patients with mid- to late-stage PD experiencing motor fluctuations.

About Parkinson's disease

Parkinson's disease is a degenerative disorder of the central nervous system that often impairs the patient's motor skills and speech. Parkinson's disease belongs to a group of conditions called movement disorders. It is characterized by muscle rigidity, tremor, a slowing of physical movement (bradykinesia) and, in extreme cases, a loss of physical movement (akinesia). The primary symptoms are the results of decreased stimulation of the motor cortex by the basal ganglia, normally caused by the insufficient formation and action of dopamine, which is produced in the dopaminergic neurons of the brain. Secondary symptoms may include high-level cognitive dysfunction and subtle language problems. Parkinson's disease is both chronic and progressive. It is estimated that more than 3 million people in the industrialized countries suffer from Parkinson's disease.

About Merck Serono

Merck Serono is the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. In the United States and Canada, EMD Serono operates as a separately incorporated affiliate of Merck Serono.

Merck Serono has leading brands serving patients with cancer (Erbitux®, cetuximab), multiple sclerosis (Rebif®, interferon beta-1a), infertility (Gonal-f®, follitropin alfa), endocrine and metabolic disorders (Saizen® and Serostim®, somatropin), (Kuvan®, sapropterin dihydrochloride), (Egrifta™, tesamorelin), as well as cardiometabolic diseases (Glucophage®, metformin), (Concor®, bisoprolol), (Euthyrox®, levothyroxine). Not all products are available in all markets.

With an annual R&D expenditure of over € 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in rheumatology.

About Merck

Merck is a global pharmaceutical and chemical company with total revenues of € 9.3 billion in 2010, a history that began in 1668, and a future shaped by more than 40,000 employees in 67 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.

For more information, please visit http://www.merckserono.com or http://www.merck.de

SOURCE Merck Serono S A